Qualitek Labs FY26: Scale-up Year, With H2 Margin Expansion and a Bigger Expansion Plan

Qualitek Labs Limited closed FY2025-26 with a sharp step-up in scale and profitability. The company reported consolidated revenue from operations of 124.52 crore in FY26, up 77 percent over FY25. EBITDA increased to 29.29 crore, up 80 percent, while profit after tax rose to 14.60 crore, up 90 percent.

The second half of the year carried most of the momentum. In H2 FY26, consolidated revenue was 70.27 crore versus 54.24 crore in H1 FY26. EBITDA rose to 18.06 crore in H2 from 11.22 crore in H1, and PAT more than doubled to 9.83 crore from 4.77 crore. Margin improvement was visible too: H2 FY26 EBITDA margin was 26 percent versus 21 percent in H1, and PAT margin was 14 percent versus 9 percent.

Qualitek operates a diversified testing, inspection and certification services platform. The presentation positions the company across automotive and defence testing, electricals and electronics, minerals and metals, pharmaceuticals, food and feed, environment and water, infrastructure materials, and medical equipment testing. This breadth matters because the company is expanding through both capex and acquisitions, and it is pushing into adjacent services such as inspections, audits and certifications.

FY26 performance: growth with improving profitability in H2

FY26 consolidated performance shows operating leverage, but the half-year split makes the story clearer. The second half delivered higher revenue, and a disproportionate share of EBITDA and PAT. In H2 FY26, gross margin improved to 88 percent from 85 percent in H1, while EBITDA margin expanded to 26 percent from 21 percent.

On a full-year basis, consolidated gross margin improved over time, reaching 87 percent in FY26 versus 85 percent in FY25. EBITDA margin in FY26 was 24 percent compared to 23 percent in FY25, while PAT margin improved to 12 percent from 11 percent.

The company also shared standalone numbers for context. Standalone revenue in FY26 was 67.6 crore, EBITDA was 16.6 crore, and PAT was 8.0 crore. However, the primary focus in the presentation is on consolidated scale, especially after consolidation became applicable from H1 FY26 onwards.

Business mix: core verticals and growth drivers

Qualitek highlights three large consolidated revenue contributors as broad ranges. Transport, defence and mechanical contributes 40 to 45 percent of consolidated revenue. Food and feed contributes 25 to 30 percent. Pharma contributes 15 to 20 percent.

Beyond these, the presentation lists a set of emerging growth verticals including inspection, audit and certifications, medical devices and packaging material testing, energy and oil and gas, consumer products, and fumigation testing.

Operationally, the company positions itself as a nationwide platform. It reports a network of 10 owned laboratories and 6 government labs operated in PPP mode, supported by 350 plus collection centres. It also reports more than 5 million tests per year and a workforce of 1200 plus employees, including 450 scientists and 363 field staff.

Geographically, the company describes a multi-city lab presence including Pune, Noida, Bhubaneswhar, Paradip, Panchkula, Chennai, Bangalore and Mumbai. It also lists international collaborations across Netherlands, United Kingdom, France, Germany, Czech Republic, Japan, China, Hong Kong, Dubai and Malaysia.

Capex and expansion: FY26 spend and FY27 pipeline

FY2025-26 included 51.3 crore of capex investment. The company links this to a mix of acquisition-led and capacity-led expansion: acquisition of a food testing lab in Mumbai, operationalisation of a second lab in Bhubaneswhar, capacity expansion of pharma and food labs in Panchkula and Chennai, new scope addition in transport and defence, and setting up a VOC testing facility in Noida. It also acquired land and building in Barwala, Panchkula for future expansion.

For FY2026-27, the company outlines a capex plan of 63 crore. The stated focus areas include M&A opportunities across pharma, food and electricals and electronics, further capacity expansion of food labs in Mumbai, Chennai and Bhubaneswhar, accreditation for inspections, audit, certification and fumigation, geographic expansions in transport and minerals segments, and new revenue streams through setting up EMI and EMC in Pune and an analytical lab in Noida.

Two near-term acquisition milestones are explicitly stated. Under the pharma growth driver, the company notes that an acquisition of a USFDA lab is underway and targeted to be commercial by June 2026. Under food and feed, a Hyderabad acquisition is expected to complete by June 2026.

Balance sheet signals: scale-up accompanied by higher leverage and goodwill

The balance sheet shows how the platform has grown. Total assets increased to 270.94 crore in FY26 from 157.92 crore in FY25. PPE and intangible assets rose to 119.47 crore from 74.95 crore. Goodwill increased to 78.12 crore from 33.04 crore, reflecting acquisition-led expansion.

On the funding side, total equity increased to 152.42 crore in FY26 from 92.78 crore in FY25. Borrowings also rose, with long-term borrowings at 60.12 crore and short-term borrowings at 32.86 crore in FY26. The company reports a debt-equity ratio of 1.25 in FY26, up from 0.83 in FY25.

Working capital items moved up as well. Trade receivables rose to 42.14 crore in FY26 from 28.86 crore in FY25. The presentation does not provide a cash flow statement, so cash conversion and working capital discipline cannot be verified from this document alone.

FY27 guidance: growth plus margin targets

The company provides explicit FY27 expectations. It guides for revenue growth of 35 to 40 percent, driven by geographic expansion and new segment additions. It expects EBITDA margins of 25 to 26 percent, and PAT margins of 15 to 17 percent.

The guidance matters because FY26 consolidated EBITDA margin was 24 percent and PAT margin was 12 percent. The company’s H2 FY26 performance shows an EBITDA margin of 26 percent and PAT margin of 14 percent, so the FY27 targets imply sustaining H2 profitability and improving further.

In the medium term, the company states an aspiration to be one of the leading global labs by 2031-32. The strategy list includes geographic expansion in automotive in South India, strengthening M&A in pharmaceuticals and food, expanding food testing in West and East regions, cross-functional synergies and key account management, expanding lab process outsourcing in multiple verticals, and building low capex business lines in audit, certification and fumigation.

Takeaways

FY26 for Qualitek Labs was defined by scale-up and a stronger second half. Consolidated revenue crossed 124 crore with rapid year-on-year growth, and margins expanded sharply in H2. The company is simultaneously building capacity, adding new capabilities such as VOC and planned EMI and EMC, and pursuing acquisitions in pharma and food.

The FY27 outlook is framed with clear numeric targets for growth and profitability, and the capex plan is quantified. At the same time, the balance sheet shows rising borrowings and a significant increase in goodwill, reflecting the cost and complexity of acquisition-led expansion. How the company integrates new assets and sustains H2-level margins will be central to tracking execution against the FY27 targets.